This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoban, D. J.
Right arrow Articles by Karlowsky, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoban, D. J.
Right arrow Articles by Karlowsky, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1999, p. 1463-1464, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients

Daryl J. Hoban,1,2,* George G. Zhanel,1,3,4 and James A. Karlowsky1,2,3

Department of Medical Microbiology1 and Faculty of Pharmacy,3 University of Manitoba, and Departments of Clinical Microbiology2 and Medicine,4 Health Sciences Centre, Winnipeg, Manitoba, Canada

Received 23 February 1999/Returned for modification 15 March 1999/Accepted 30 March 1999

Fluconazole-resistant Candida albicans and intrinsically fluconazole-resistant Candida species have been reported as bloodstream isolates. However, an association between the isolation of fluconazole-resistant Candida from the bloodstream and patient risk factors for fungemia has not been established. The purpose of this study was to determine the prevalence of fluconazole resistance in bloodstream isolates of Candida species and Cryptococcus neoformans collected from patients with neutropenia, one of the most important risk factors for fungemia. MICs of voriconazole, fluconazole, itraconazole, ketoconazole, amphotericin B, and flucytosine were determined by the National Committee for Clinical Laboratory Standards M27-A method (1997). Voriconazole, on a per-weight basis, was the most active azole tested. Fluconazole resistance (MIC >=  64 µg/ml) was not identified in any of the C. albicans (n = 513), Candida parapsilosis (n = 78), Candida tropicalis (n = 62), or C. neoformans (n = 38) isolates tested.

* Corresponding author. Department of Clinical Microbiology, Health Sciences Centre, MS673, 820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-1191. Fax: (204) 787-4699. E-mail: dhoban{at}hsc.mb.ca.

Antimicrobial Agents and Chemotherapy, June 1999, p. 1463-1464, Vol. 43, No. 6
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Dias, A. L. T., Matsumoto, F. E., Melhem, M. S. C., da Silva, E. G., Auler, M. E., de Siqueira, A. M., Paula, C. R. (2006). Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.. J Med Microbiol 55: 1693-1699 [Abstract] [Full Text]  
  • van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A., Nosanchuk, J. D. (2004). Effects of Voriconazole on Cryptococcus neoformans. Antimicrob. Agents Chemother. 48: 2014-2020 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J., Diekema, D. J. (2002). In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods. Antimicrob. Agents Chemother. 46: 3518-3521 [Abstract] [Full Text]  
  • Girmenia, C., Tuccinardi, C., Santilli, S., Mondello, F., Monaco, M., Cassone, A., Martino, P. (2000). In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies. J Antimicrob Chemother 46: 479-484 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»